The UK and US have announced a significant trade agreement that will ensure zero duties on UK drug shipments going into the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on pharmaceuticals through the National Health Service (NHS). This move guarantees that duties on these vital products will be held at nothing for a duration of three years.
This agreement follows earlier statements to significantly raise duties on patented pharmaceutical products, with figures mentioned as high as one hundred percent.
"This deal with the United Kingdom strengthens the global environment for innovative medicines and establishes much-needed balance to American-British pharmaceutical trade," a statement noted.
Trade Impact
Medicines constitute one of the Britain's biggest export categories to the US, which is by far the primary buyer for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months to the end of the third quarter, the UK sold medicines worth billions to the US. This figure represented nearly one-fifth of all goods exports in that period.
"This agreement secures jobs, boosts investment and facilitates the UK to emerge as a international leader for life sciences," a government official stated.
Specific NHS Changes
The pact entails several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a target to increase overall health service expenditure on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Previously, rebates topped twenty percent.
Broader Context
The pact follows a protracted row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were exacerbated by assertions that US patients were charged a premium for the same drugs than people in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been paused or cancelled, while substantial expansions have been pledged toward American operations.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the past decade.
